Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATEMarket Beat·22 hours agoFATE+1.98%
Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)Market Beat·1 day ago, 08:18 AMFATE+1.98%
Fate Therapeutics starts potentially registrational Phase 2 RECLAIM-LN trial of FT819 in lupus nephritisPUBT·1 day ago, 06:01 AMFATE+1.98%
Fate Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 2.082 MEarnings Watch·2 days ago, 07:37 AMFATE+1.98%
Fate Therapeutics grants new-hire inducement equity awards, including 37,300 options at $2.45PUBT·Aug 3 at 03:10 PMFATE+1.98%
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by BrokeragesMarket Beat·Jul 26 at 01:44 AMFATE+1.98%
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Sessionbenzinga_article·Jul 15 at 07:02 AMPOOL-2.86%ELV+0.53%
Fate Therapeutics wins FDA IND clearance for dual-target CAR-T candidate FT839PUBT·Jul 9 at 07:33 AMFATE+1.98%
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product CandidateUnusual Whales·Jul 9 at 07:31 AMFATE+1.98%
Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54Simplywall·Jul 6 at 11:06 AMFATE+1.98%
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual MeetingUnusual Whales·Jul 6 at 07:31 AMFATE+1.98%
Fate Therapeutics reports preliminary FT819 CAR-T data showing skin score improvement in systemic sclerosis patientsPUBT·Jul 6 at 07:31 AMFATE+1.98%
